| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8940774 | European Urology Oncology | 2018 | 7 Pages |
Abstract
In this study we found that metastatic prostate cancer with loss of the PTEN switch may benefit more from docetaxel than from abiraterone.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, Susana Miranda, Diletta Bianchini, Zafeiris Zafeiriou, Spyridon Sideris, Ana Ferreira, Ines Figueiredo, Semini Sumanasuriya, Joaquin Mateo,